Mika K. Derynck

2.7k total citations
34 papers, 1.5k citations indexed

About

Mika K. Derynck is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Mika K. Derynck has authored 34 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Molecular Biology. Recurrent topics in Mika K. Derynck's work include Monoclonal and Polyclonal Antibodies Research (14 papers), HER2/EGFR in Cancer Research (9 papers) and CAR-T cell therapy research (8 papers). Mika K. Derynck is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), HER2/EGFR in Cancer Research (9 papers) and CAR-T cell therapy research (8 papers). Mika K. Derynck collaborates with scholars based in United States, United Kingdom and Canada. Mika K. Derynck's co-authors include Daniel Khodabakhsh, Daisuke Nonaka, Jen-Chywan Wang, Keith R. Yamamoto, Chris Haqq, Christopher M. Haqq, Michael J. Garabedian, Inez Rogatsky, Beatrice Darimont and David E. Allison and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mika K. Derynck

34 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mika K. Derynck United States	15	648	553	331	308	281	34	1.5k
Erling A. Høivik Norway	25	809 1.2×	304 0.5×	314 0.9×	170 0.6×	344 1.2×	55	1.6k
Yasir H. Ibrahim United States	12	1.1k 1.7×	828 1.5×	140 0.4×	305 1.0×	249 0.9×	22	1.6k
Cecilia J. Proietti Argentina	22	691 1.1×	689 1.2×	327 1.0×	97 0.3×	298 1.1×	37	1.3k
Svetlana Bajalica‐Lagercrantz Sweden	18	797 1.2×	665 1.2×	842 2.5×	165 0.5×	309 1.1×	52	2.0k
Sandra Cascio United States	21	917 1.4×	405 0.7×	348 1.1×	99 0.3×	487 1.7×	41	1.7k
Hisashi Hirakawa Japan	24	805 1.2×	839 1.5×	741 2.2×	286 0.9×	752 2.7×	63	2.0k
Gerald E. Stoica United States	9	771 1.2×	388 0.7×	249 0.8×	204 0.7×	183 0.7×	9	1.3k
Corinne M. Silva United States	23	1.0k 1.6×	942 1.7×	276 0.8×	151 0.5×	320 1.1×	34	1.9k
Purna A. Joshi Canada	11	764 1.2×	901 1.6×	348 1.1×	136 0.4×	324 1.2×	13	1.4k
Martín A. Rivas Argentina	17	761 1.2×	845 1.5×	136 0.4×	477 1.5×	397 1.4×	27	1.6k

Countries citing papers authored by Mika K. Derynck

Since Specialization

Citations

This map shows the geographic impact of Mika K. Derynck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mika K. Derynck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mika K. Derynck more than expected).

Fields of papers citing papers by Mika K. Derynck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mika K. Derynck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mika K. Derynck. The network helps show where Mika K. Derynck may publish in the future.

Co-authorship network of co-authors of Mika K. Derynck

This figure shows the co-authorship network connecting the top 25 collaborators of Mika K. Derynck. A scholar is included among the top collaborators of Mika K. Derynck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mika K. Derynck. Mika K. Derynck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cattaruzza, Fiore, Milton To, Caitlin Koski, et al.. (2023). Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. Nature Cancer. 4(4). 485–501. 50 indexed citations

Cattaruzza, Fiore, Caitlin Koski, Trang Dao-Pick, et al.. (2021). Abstract PS17-11: Her2-xpat, a novel protease-activatable prodrug t-cell engager (tce), exhibits potent t-cell activation and efficacy in her2 tumors, yielding large predicted safety margins based on non-human primate (nhp). Cancer Research. 81(4_Supplement). PS17–11. 1 indexed citations

Cattaruzza, Fiore, Caitlin Koski, Milton To, et al.. (2021). Abstract 1824: HER2-XPAT, a novel protease-activatable T-cell engager (TCE) with potent T-cell activation and efficacy in solid tumors and large safety margins in non-human primate (NHP). Cancer Research. 81(13_Supplement). 1824–1824. 1 indexed citations

Cattaruzza, Fiore, Caitlin Koski, Daniel R. Hostetter, et al.. (2020). 1060P HER2-XPAT, a novel protease-activatable pro-drug T-cell engager (TCE), engineered to address on-target, off tumour toxicity and provide large predicted safety margins in non-human primate (NHP). Annals of Oncology. 31. S723–S723. 1 indexed citations

Cattaruzza, Fiore, et al.. (2020). Abstract 3376: HER2-XPAT and EGFR-XPAT: Pro-drug T-cell engagers (TCEs) engineered to address on-target, off-tumor toxicity with potent efficacy in vitro and in vivo and large safety margins in NHP. Cancer Research. 80(16_Supplement). 3376–3376. 4 indexed citations

Ang, Joo Ern, Yasmin J. Asad, Alan T. Henley, et al.. (2016). Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Molecular Cancer Therapeutics. 15(6). 1412–1424. 16 indexed citations

Gendreau, Steven, Stephen Johnston, Peter Schmid, et al.. (2016). Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI). Cancer Research. 76(4_Supplement). PD6–3. 2 indexed citations

Spoerke, Jill M., Steven Gendreau, Kimberly Walter, et al.. (2016). Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nature Communications. 7(1). 11579–11579. 219 indexed citations

Krop, IE, Antonio C. Wolff, EP Winer, et al.. (2010). Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer. Cancer Research. 70(24_Supplement). P6–15. 8 indexed citations

10.

Wagner, Andrew J., Patricia LoRusso, Raoul Tibes, et al.. (2009). A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 3501–3501. 53 indexed citations

11.

Lin, Amy, Brian I. Rini, Mika K. Derynck, et al.. (2007). A Phase I Trial of Docetaxel/Estramustine/Imatinib in Patients with Hormone-Refractory Prostate Cancer. Clinical Genitourinary Cancer. 5(5). 323–328. 24 indexed citations

12.

Makhija, Sharmila, F. Ueland, Don S. Dizon, et al.. (2007). Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology. 25(18_suppl). 5507–5507. 19 indexed citations

13.

Gordon, Michael S., Daniela Matei, Carol Aghajanian, et al.. (2006). Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status. Journal of Clinical Oncology. 24(26). 4324–4332. 187 indexed citations

14.

Amler, Lukas C., Michael S. Gordon, Andreas C. Strauß, et al.. (2006). Identification of predictive markers of clinical activity from a phase II trial of single agent pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer (OC). Journal of Clinical Oncology. 24(18_suppl). 3001–3001. 1 indexed citations

15.

Allison, David E., et al.. (2005). Pharmacokinetics (PK) of pertuzumab (rhuMAb 2C4) in phase II studies of ovarian, breast, prostate, and lung cancers. Journal of Clinical Oncology. 23(16_suppl). 2532–2532. 7 indexed citations

16.

Wang, Jen-Chywan, Mika K. Derynck, Daisuke Nonaka, et al.. (2004). Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proceedings of the National Academy of Sciences. 101(44). 15603–15608. 257 indexed citations

17.

Lawrence, H. Jeffrey, Sheri T. Dorsam, Hideaki Ohta, et al.. (2004). Activation of Stem-Cell Specific Genes by HOXA9 and HOXA10 Homeodomain Proteins in CD34+ Human Cord Blood Cells.. Blood. 104(11). 3227–3227. 4 indexed citations

18.

Oh, William, Philip W. Kantoff, Graham Jones, et al.. (2004). Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer. Journal of Clinical Oncology. 22(18). 3705–3712. 90 indexed citations

19.

Dorsam, Sheri T., Glenn Dorsam, Mika K. Derynck, et al.. (2003). The transcriptome of the leukemogenic homeoprotein HOXA9 in human hematopoietic cells. Blood. 103(5). 1676–1684. 72 indexed citations

20.

Rogatsky, Inez, Jen-Chywan Wang, Mika K. Derynck, et al.. (2003). Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proceedings of the National Academy of Sciences. 100(24). 13845–13850. 204 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact